MEDICAL IP CO., LTD.


Associated tags: Diagnosis, Education, Medicine, Disease, AI, Medical device, Sarcopenia, Safety, Skin, US FDA, Bias, FDA, Health, DSM-IV codes, Patient, US, DXA, Google Images, Connective tissue, IP, Software, Cancer, 3D, Bioelectrical impedance analysis

Locations: TEXAS, CALIFORNIA, NEW YORK, CT, SEOUL, UNITED STATES

"MEDICAL IP, Unveiling of Digital Twin Simulation Platform at NVIDIA GTC 2024…" Jensen Huang emphasizes Omniverse Platform in his keynote

Retrieved on: 
Wednesday, March 27, 2024

At GTC 2024, which attracted a record-breaking 300,000 visitors, MEDICAL IP was invited as an 'NVIDIA Partner' to unveil MEDIP, the AI digital twin and simulation software, as one of the premier use cases of NVIDIA Omniverse.

Key Points: 
  • At GTC 2024, which attracted a record-breaking 300,000 visitors, MEDICAL IP was invited as an 'NVIDIA Partner' to unveil MEDIP, the AI digital twin and simulation software, as one of the premier use cases of NVIDIA Omniverse.
  • MEDICAL IP's 'MEDIP X NVIDIA Omniverse' is a convergence platform, based on AI digital twin, which allows real-time 3D modeling of medical images in virtual space, as well as segmentation and modeling through AI.
  • At GTC 2024, MEDICAL IP's demonstration of simulating the human body in the metaverse through Omniverse garnered significant attention from GTC attendees.
  • He further expressed, "Digital twin simulation based on individual patient data requires advanced technology.

MEDICAL IP Received US FDA 510(k) Clearance for DeepCatch, AI Software for Whole-Body Composition CT Quantification

Retrieved on: 
Monday, June 26, 2023

DeepCatch is the only FDA cleared AI software that automatically analyzes various body components such as skin, bone, muscle, visceral fat, subcutaneous fat, internal organ, and central nervous system through whole-body CT.

Key Points: 
  • DeepCatch is the only FDA cleared AI software that automatically analyzes various body components such as skin, bone, muscle, visceral fat, subcutaneous fat, internal organ, and central nervous system through whole-body CT.
  • Accordingly, this FDA Clearance will provide an opportunity for DeepCatch, which calculates body composition information from CT, to be quickly introduced to the medical field in the United States.
  • It will contribute to the development of the medical industry through fast, accurate, and efficient CT-based body composition analysis technology."
  • DeepCatch can be introduced to any medical institution around the world that takes CT scans, so with this FDA Clearance, we will be able to accelerate our strategy for global expansion."